CU Innovations specializes in commercializing technology, developing ventures, and building business partnerships. We are the resource for biomedical technology commercialization for both the University of Colorado Anschutz Medical Campus and Denver Campus. For assistance, contact one of our team members below or complete this contact form.
(303) 724 - 0222 | firstname.lastname@example.org
Kimberly Muller is the Executive Director of CU Innovations where she leads innovation for the University of Colorado Anschutz Medical Campus. Ms. Muller’s business development responsibilities include investing, company creation, innovation management, forming key strategic industry partnerships, and licensing. Large-scale industry collaborations have been established in areas such as AI and drug development. She also manages several funds, including an innovation grant fund, and a nearly $50 million venture fund.
Kimberly joined the University of Colorado from Yale University where she was formerly the Deputy Director of the Yale Entrepreneurial Institute (YEI), and managed New Ventures in the Office of Cooperative Research. During Kimberly’s tenure, Yale’s Office of Cooperative Research started more than 70 new ventures that have raised over $5 billion in investor capital.
Previously, Kimberly started and sold companies in the biotech, tech, and clean energy fields, companies included Curagen Corporation (acquired by Celldex Therapeutics), 454 Life Science (acquired by Roche), and Arbor Fuel, a biofuel company that utilized recombinant microorganisms for the production of ethanol and butanol. Kimberly began her career in New York as a patent attorney for Chadbourne and Parke, LLP.
Kimberly has a graduate degree in Genetics, and received her law degree with highest honors from the University of Connecticut School of Law.
(303) 724 - 4068 | email@example.com
James joined the Licensing Group of CU Innovations in January 2018. As the Manager of Pharmaceutical Development and Intellectual Property, he works closely with research scientists helping transition their creations from the laboratory to the public.
His legal practice focuses on the acquisition and development of intellectual property, including the filing and prosecution of patents, as well as the negotiation and licensing of patented inventions. He is also actively engaged with campus investigators in advising how to commercialize and develop novel medications and formulations discovered at the Anschutz Medical Campus. James has extensive experience with both healthcare and technology innovation, having worked as a pharmacist for Walgreens Co., an intellectual property attorney with Morris, Nichols, Arsht and Tunnell, LLP, and a research assistant at ImmunoTox, Inc.
James obtained his Doctor of Pharmacy and Masters of Pharmacy Administration from the University of Mississippi. He earned his Juris Doctor from William and Mary Law School. He received a Bachelor of Science in Chemistry from James Madison University. James is admitted to practice law in Delaware, Mississippi and Colorado. He is also a licensed pharmacist in Mississippi and Colorado.
(303) 724-1255 | firstname.lastname@example.org
(303) 724 - 0220 | email@example.com
(303) 724 - 1042 | firstname.lastname@example.org
(303) 724 - 1061 | email@example.com
(303) 724 - 1084 | firstname.lastname@example.org
(303) 724 - 1098 | email@example.com
Dallas Martin serves as Associate Counsel in the CU Innovations Office at the University of Colorado Anschutz Medical Campus.
(303) 724 - 0184 | firstname.lastname@example.org
Copy Copy Copy
(303) 724 - 1329 | email@example.com
(303) 724 - 4058 | firstname.lastname@example.org
(303) 724 - 1039 | email@example.com
(303) 724 - 1042 | firstname.lastname@example.org
(303) 724 - 4003 | email@example.com
(303) 724 - 1068 | firstname.lastname@example.org
Rolfe manages the CU Innovations brand, communications, and website.
(303) 724 - 3720 | email@example.com
Correspondence, scheduling, and directions
Tyler joined the CU Innovations team in June 2019 as a Technology Marketing Analyst. He is a Materials Chemistry PhD student at the University of Colorado Boulder campus. Tyler's research concerns semiconductor processing where he and his lab work closely with companies like Intel, Tokyo Electron, and Lam Research to develop processes for fabricating cutting-edge nanotechnology devices. Currently he is working on etching nanoparticles for applications in solar energy. Tyler has a Bachelor of Chemistry and Mathematics from Elmira College in upstate New York.
Nina is currently a student in the Biomedical Science and Biotechnology Master's program. She conducts research in the Department of Neurology focused on identifying biomarkers for neurodegenerative diseases using mosaic aneuploidy. Previously, she studied the expression and regulation of the Rap genes in breast cancer. Nina has a B.S. in Biology with a minor in Chemistry from the University of St. Thomas in Minnesota.
Melissa is currently a third year medical student at the University of Colorado Anschutz Medical Campus. She previously attended the University of Colorado Boulder where she received a BS in Chemical and Biological Engineering. She then went on to receive her PhD in Bioengineering at University of Colorado Denver. Melissa's primary research focuses on the design, synthesis, and characterization of multifunctional biomaterials for clinical applications. She has worked on a variety of research projects aimed at establishing platforms for targeted drug delivery, injectable biomaterials for tissue engineering, and nanoparticle materials for diagnostic use. Her most recent research involves the development of a new diagnostic approach for HER2-positive breast cancer.